Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with vWD involves significant variability due to bleeding manifestations and treatment options. The new recommendations from 2021 regarding the care of people with vWD are evidence-based and supported by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation USA (NHF), and the World Federation of Hemophilia (WFH). We bring you a concise summary of the key points.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
